# Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

> **NCT05366829** · PHASE2 · RECRUITING · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 35 (estimated)

## Conditions studied

- Carcinoma, Hepatocellular
- Liver Cell Carcinoma

## Interventions

- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT05366829
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-25
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-01-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05366829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05366829, "Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05366829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*